Wednesday, December 06, 2023 San Antonio Breast Cancer Symposium (SABCS) takes place this year at the Henry B. Gonzalez Convention Centre, December 5-9, 2023. SABCS is an International scientific symposium for scientists and clinicians in breast cancer. The event is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers. CCTG at SABCS CCTG MA.27 – A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer Time: December 6, 2023; 12:00-2:00 PM CT Session: Poster Session 1 Abstract: Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial. Authors: Chapman JA, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss P, Ingle J, Ellis M, Sledge Jr G, Budd G, Rabaglio M, Ansari R, Tozer R, D'Souza D, Chalchal H, Spadafora S, Stearns V, Perez EA, Gelmon K, Whelan T, Elliott C, Shepherd L, Chen B, Taylor K CCTG MA.28/NCCTG N9831 – Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment For Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer Time: December 7, 2023; 5:00-7:00 PM CT Session: Poster Session 4 Abstract: MHC Class I and II Expression, Functional Tertiary Lymphoid Structure (TLS), and Outcomes in Early-Stage HER2-Positive (HER2+) Breast Cancer in NCCTG N9831 (Alliance) Authors: Chumsri S, Shachner T, Li Z, Norton N, Moreno-Aspitia A, Colon-Otero G, Perez E, Nassar A, Thompson E, Knutson K CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer Time: December 6, 2023; 12:00-2:00 PM CT Session: Poster Session 1 Abstract: The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study Authors: Agostinetto E, Pfeiler G, Hlauschek D, Mayer E, Lambertini M, de Azambuja E, Bellet- Ezquerra M, Meisel J, Rubovszky G, Zdenkowski N, Novik Y, Ruíz-Borrego M, Gelmon K, Mamounas E, Iwata H, Lu D, Sölkner L, Fesl C, Gnant M, DeMichele A CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer Time: December 6, 2023; 12:00-2:00 PM CT Session: Poster Session 1 Abstract: Clinical characterization, prognostic and predictive values of HER2-low in early breast cancer in the PALLAS trial Authors: Nader-Marta G, Singer CF, Hlauschek D, DeMichele A, Tarantino P, Pfeiler G, Martín M, Balko J, Nowecki Z, Balic M, Brufsky A, Chan A, Morris PG, Haddad T, Loibl S, Y Liu, Sölkner L, Fesl C, Mayer E, Gnant M CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer Time: December 7, 2023; 12:00-2:00 PM CT Session: Poster Session 3 Abstract: Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05) Authors: Kantor O, Fayanju O, Dueck A, Gnant M, Burstein H, Goetz M, Isaacs C, Shepherd L, Hahn O, Anderson D, Miller K, Rugo H, Traina T, Dayao Z, Clifton K, Winer E, Wolff A, Wolmark N, Lu D, O'Brien P, Scovil S, DeMichele A, Mayer E CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer Time: December 8, 2023; 8:15-11:15 AM CT Session: General Session 3 Abstract: Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer Authors: Stover D, Hlauschek D, Mayer E, Symmans WF, Watson M, Barozzi I, Filipits M, Ballman K, Bellet- Ezquerra M, Balko J, Rubovszky G, Zdenkowski N, Brufsky A, Steger G, Isaacs C, Loibl S, Henao F, Regan M, Liu Y, Fesl C, O'Brien P, DeMichele A, Gnant M, Metzger O. CCTG MAC.18/Alliance A221405 – POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy Time: December 6, 2023; 8:15-11:15 AM CT Session: Oral General Session 2 Abstract: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy Authors: Azim H, Niman S, Partridge A, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal A, Kroep J, Mailliez A, Warner E, Borges V, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe J, Ruíz-Borrego M, Moore H, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar N, Spanic T, Ruddy K, Piccart M, Korde L, Goldhirsch A, Gelber R, Pagani O, Peccatori FA CCTG MAC.28 – A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </=18 Breast Cancer (DEBRA) Time: December 6, 2023; 12:00-2:00 PM CT Session: Poster Session 1 Abstract: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007 Authors: White J, Cecchini R, Harris E, Mamounas E, Stover D, Ganz P, Jagsi R, Anderson S, Bergom C, Théberge V, El-Tamer M, Zellars R, Shumway E, Chen GP, Julian T, Wolmark N CCTG MAC.29/Alliance A012103 – OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy Time: December 7, 2023; 5:00-7:00 PM CT Session: Poster Session 4 Abstract: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103) Authors: Tolaney S, Ballman K, Perou CM, Cescon D, Gatti-Mays M, Blinder V, Rosenberg S, Mittendorf E, Weiss A, Rugo H, Ho A, Casey D, Singh B, Smieliauskas F, Abdou Y, Damarla V, Meisel J, Carey L, Partridge A
